Home › NCT06971991

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

qDSA Blood Flow Measurement in Patients Undergoing Transarterial Embolization (TAE) of the Liver

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule

Exclusion Criteria:

* Pregnancy or breastfeeding
* Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.
* Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.
* Patients with a physical or psychological condition that would impair study participation.
* The patient is judged unsuitable for study participation by the Investigator for any other reason

About the study

The purpose of this research is to evaluate a new technique, quantitative digital subtraction angiography (qDSA), to measure blood flow during liver embolization procedures. Liver embolization is a way of treating liver tumors by blocking blood flow to it. The qDSA technique could help doctors ensure the blood flow to the tumor is decreased by the right amount by calculating blood flow before, during, and after the procedure. Up to 20 participants will be enrolled for 1 study visit and data collection for up to 6 months.

What is being tested

• qDSA Blood Flow Measurement (device)

Sponsor: University of Wisconsin, Madison · Participants: 20 · Started: Mar 13, 2025

Contact the study team

• Radiology Coordinators · Phone: 608-282-8349

Official record on ClinicalTrials.gov — NCT06971991

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.